Abstract
This paper reports the results from a statistical analysis of pharmaceutical price negotiations in Germany, where the pricing system was changed in 2011 in order to tie prices more to the benefits of the pharmaceuticals. A multiple linear regression of 187 pharmaceuticals which were assessed from 2011 to 2017 suggests that, despite the change, the manufacturers' launch strategy (freely chosen first year price) still has a major impact on pricing while the impact of the additional benefit remains comparably small. Moreover, the data suggest that the assessment of the Federal Joint Committee - while not yet existing at the point - best explains the manufacturer's launch strategy, indicating that manufacturers know more than they reveal.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
